ID   NORR_VIBVU              Reviewed;         510 AA.
AC   Q8D4F9;
DT   25-MAR-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2003, sequence version 1.
DT   03-AUG-2022, entry version 128.
DE   RecName: Full=Anaerobic nitric oxide reductase transcription regulator NorR {ECO:0000255|HAMAP-Rule:MF_01314};
GN   Name=norR {ECO:0000255|HAMAP-Rule:MF_01314}; OrderedLocusNames=VV2_1342;
OS   Vibrio vulnificus (strain CMCP6).
OC   Bacteria; Proteobacteria; Gammaproteobacteria; Vibrionales; Vibrionaceae;
OC   Vibrio.
OX   NCBI_TaxID=216895;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=CMCP6;
RA   Rhee J.H., Kim S.Y., Chung S.S., Kim J.J., Moon Y.H., Jeong H., Choy H.E.;
RT   "Complete genome sequence of Vibrio vulnificus CMCP6.";
RL   Submitted (DEC-2002) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Required for the expression of anaerobic nitric oxide (NO)
CC       reductase, acts as a transcriptional activator for at least the norVW
CC       operon. Activation also requires sigma-54. {ECO:0000255|HAMAP-
CC       Rule:MF_01314}.
CC   -!- PATHWAY: Nitrogen metabolism; nitric oxide reduction.
CC       {ECO:0000255|HAMAP-Rule:MF_01314}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AE016796; AAO08229.1; -; Genomic_DNA.
DR   RefSeq; WP_011082225.1; NC_004460.2.
DR   AlphaFoldDB; Q8D4F9; -.
DR   SMR; Q8D4F9; -.
DR   EnsemblBacteria; AAO08229; AAO08229; VV2_1342.
DR   GeneID; 66966719; -.
DR   KEGG; vvu:VV2_1342; -.
DR   HOGENOM; CLU_000445_125_3_6; -.
DR   OMA; LRYEAHQ; -.
DR   UniPathway; UPA00638; -.
DR   Proteomes; UP000002275; Chromosome 2.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IEA:UniProtKB-UniRule.
DR   GO; GO:0000160; P:phosphorelay signal transduction system; IEA:UniProtKB-UniRule.
DR   Gene3D; 3.30.450.40; -; 1.
DR   Gene3D; 3.40.50.300; -; 1.
DR   HAMAP; MF_01314; NorR; 1.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR003018; GAF.
DR   InterPro; IPR029016; GAF-like_dom_sf.
DR   InterPro; IPR009057; Homeobox-like_sf.
DR   InterPro; IPR023944; NorR.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR002078; Sigma_54_int.
DR   InterPro; IPR025662; Sigma_54_int_dom_ATP-bd_1.
DR   InterPro; IPR025943; Sigma_54_int_dom_ATP-bd_2.
DR   InterPro; IPR025944; Sigma_54_int_dom_CS.
DR   Pfam; PF01590; GAF; 1.
DR   Pfam; PF00158; Sigma54_activat; 1.
DR   SMART; SM00382; AAA; 1.
DR   SMART; SM00065; GAF; 1.
DR   SUPFAM; SSF46689; SSF46689; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   PROSITE; PS00675; SIGMA54_INTERACT_1; 1.
DR   PROSITE; PS00676; SIGMA54_INTERACT_2; 1.
DR   PROSITE; PS00688; SIGMA54_INTERACT_3; 1.
DR   PROSITE; PS50045; SIGMA54_INTERACT_4; 1.
PE   3: Inferred from homology;
KW   ATP-binding; DNA-binding; Nucleotide-binding; Transcription;
KW   Transcription regulation.
FT   CHAIN           1..510
FT                   /note="Anaerobic nitric oxide reductase transcription
FT                   regulator NorR"
FT                   /id="PRO_0000081159"
FT   DOMAIN          188..417
FT                   /note="Sigma-54 factor interaction"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_01314"
FT   DNA_BIND        486..505
FT                   /note="H-T-H motif"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_01314"
FT   BINDING         216..223
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_01314"
FT   BINDING         279..288
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_01314"
SQ   SEQUENCE   510 AA;  56617 MW;  1735872999CE0D8C CRC64;
     MTSLIAQWLH ITQDLNSALT RQARFDTLLT TIRDVLNCDS SALLLFEDQH FKPLAINGLA
     KEVLGRRFSI EQHPRLEAIA RAGDIVRFPS ESTLPDPYDG LITNHQGKLH VHSCIGLPLL
     IDDQLIGAIT IDALDPNQFD QLKNQELRFI SALAAGGLHT ALLLEQLETQ ASLPRESYAE
     KRTLSNEIIG NSQGMRTLQD QIDAVANTEL SVLVMGETGV GKELVANAIH HRSDRASNNL
     VYLNCAALPE SVAESELFGH IKGAFTGAIS HRKGKFEQAD GGTLFLDEVG ELSLELQAKL
     LRALQYGDIQ RVGDDRHIRV NTRIVAATNR VLHEEVKAGR FRADLYHRLS VFPLHVPPLR
     EREEDVILLA GFFAEQVRGK LGLHSVRLSP SLVAELREYH WPGNVRELEH VIKRAAVLAK
     ARTPQMDIEL ISQDFDIKTP TSPMMPTVAA SQAQHEIHSD IGLKQATDAF QKKLILRALE
     SNQGNWAATA RQLELDSGNL HRLAKRLGIK